影像引导治疗在结直肠癌转移性疾病管理中的作用
欧洲肿瘤内科学会(ESMO)强调寡转移疾病可采用局部消融策略以改善疾病控制,工具箱包括手术R0切除、经皮消融和动脉内治疗,选择由多学科团队决定。影像引导治疗为肝、肺、骨转移提供微创选择,经皮消融通过探针递送热、冷或电脉冲,射频消融是小转移灶的主要手段,肝动脉灌注化疗和选择性内放射治疗针对不可切除肝转移。
要点
- ESMO推荐寡转移疾病可采用局部消融策略,包括手术R0切除、经皮消融和动脉内治疗,选择由多学科团队决定。
- 射频消融是小转移灶经皮消融的主要手段,对小于3厘米、远离肝门和大血管、影像引导下完美可见的转移灶,局部控制率约90%。
- 结直肠肺转移射频消融的5年总生存率为56.0%,直径小于3厘米的转移灶控制率为91.6%。
核心结论
- 影像引导治疗为结直肠癌肝、肺、骨转移提供微创治疗选择,通过保留远处健康器官或病变器官部分避免毒性,局部消融可改善疾病控制。
研究设计与样本
- 综述,基于欧洲肿瘤内科学会(ESMO)关于寡转移疾病局部消融策略的论述,总结影像引导治疗在结直肠癌转移性疾病管理中的作用。
主要发现
- 射频消融是经皮消融的主要手段,对小于3厘米、远离肝门和大血管、影像引导下完美可见的转移灶,局部控制率约90%。
- 结直肠肺转移射频消融的5年总生存率为56.0%,直径小于3厘米的转移灶控制率为91.6%,结果与手术系列相当。
- 肝动脉灌注化疗一线治疗反应率约90%,约40%患者转化为手术;对既往静脉奥沙利铂失败患者再次挑战奥沙利铂肝动脉灌注化疗显示令人印象深刻的反应率。
- 选择性内放射治疗联合全身治疗作为一线治疗时,近期显示肝脏无进展生存获益。
关键数值与推荐
- ESMO推荐的局部消融工具箱包括手术R0切除、经皮消融和动脉内治疗,选择由多学科团队决定。
- 经皮消融通过插入探针局部递送热(射频、微波)、极端冷(冷冻消融)或电脉冲(电穿孔)。
- 不可切除、不可消融的肝转移可通过肝动脉灌注化疗或选择性内放射治疗靶向。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The European Society for Medical Oncology (ESMO) have stressed that the option for treating oligometastatic disease is a strategy of local ablative therapy, the goal of which is to improve disease control. The spectrum of the local ablative therapy toolbox described by the ESMO includes surgical R0 resection, percutaneous ablation and intra-arterial therapies, the choice of treatment being left to the multidisciplinary team. Interventional therapy involving image-guided treatment offers the possibility of less invasive treatments for colorectal cancer metastases in the liver, lung and bone by preserving from toxicity distant healthy organs or even parts of the diseased organs. Oligometastases can be targeted by image-guided puncture for percutaneous ablation by delivering locally, through inserted probes, heat (radiofrequency, microwaves), extreme cold (cryoablation) or electric pulses (electroporation). Radiofrequency (RFA) is the mainstay of percutaneous ablation and provides local control rates of around 90% when metastases are small (<3 cm), located away from hilum and large vessels, and perfectly visible under imaging guidance. The lung provides a specific environment with excellent visibility of the target tumour, and insulation of the tumour by the healthy lung improves thermal delivery. RFA of colorectal lung metastases provides a 5-year overall survival of 56.0%, with a 91.6% control rate for metastases with a diameter <3 cm. These results are comparable to results of surgical series. Non-resectable, non-ablatable liver metastases can be targeted through their preferential arterial vascularisation with hepatic arterial infusion chemotherapy (HAIC) or selective internal radiation therapy (SIRT) with radioactive microspheres. HAIC with oxaliplatin has demonstrated an impressive response rate when patients who have previously failed intravenous oxaliplatin are rechallenged. The response rate in first-line therapy is around 90%, with conversion to surgery in roughly 40% of patients. SIRT has recently demonstrated a benefit for progression-free survival in the liver when used as first-line treatment in combination with systemic therapy.
引用
- de Baere T, Tselikas L, Yevich S, et al. The role of image-guided therapy in the management of colorectal cancer metastatic disease. Eur J Cancer. 2017. PMID: 28237869. doi:10.1016/j.ejca.2017.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。